Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Genus Pharmaceuticals Limited, T/A Genus Pharmaceuticals, Linthwaite, Huddersfield, HD7 5QH, UK
Fenofibrate 160 mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablet. White to off-white oblong 15mm x 7mm tablet. |
Fenofibrate 160 mg.
Excipients with known effect: Each Fenofibrate 160 mg tablet contains lactose monohydrate 238.45 mg.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Fenofibrate |
Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated via activation of Peroxisome Proliferator Activated Receptor type α (PPARα). Through activation of PPARα, fenofibrate increases lipolysis and elimination of atherogenic triglyceride rich particles from plasma by activating lipoprotein lipase and reducing production of Apoprotein C-III. |
| List of Excipients |
|---|
|
Sodium laurilsulfate |
Blister strips (PVC/PVDC – Aluminium).
Boxes of 10, 20, 28, 30, 50, 84, 90, 98 and 100 tablets.
Hospital pack sizes: 280 and 300 tablets.
Not all pack sizes may be marketed.
Genus Pharmaceuticals Limited, T/A Genus Pharmaceuticals, Linthwaite, Huddersfield, HD7 5QH, UK
PL 06831/0204
13/07/2011
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
